Selank Dosing & Reconstitution Guide

Selank can be administered via intranasal or subcutaneous routes, with intranasal delivery often preferred due to its rapid onset of effects. Research indicates that for intranasal use, a dosing range of 250 to 500 micrograms per nostril, administered 2 to 3 times daily, is common. In contrast, subcutaneous administration typically involves a daily dose of 250 to 750 micrograms. The dosing regimen often follows a cycle of 2 to 4 weeks of administration, followed by a 1 to 2-week break to assess tolerance and effects. For optimal cognitive enhancement, studies suggest timing doses in the morning and afternoon, while evening doses may be less favorable due to potential interference with sleep.

For research purposes, Selank is typically provided in a lyophilized form, with a standard vial size of 5 mg. Reconstitution involves adding 5 mL of sterile water, resulting in a concentration of 1 mg/mL. This concentration facilitates precise dosing for experimental protocols. It is critical that reconstitution is performed under sterile conditions to prevent contamination, and researchers should ensure that the solution is mixed thoroughly to achieve a uniform distribution of the peptide. Proper techniques in reconstitution are essential for maintaining the integrity of the peptide and ensuring reliable experimental outcomes.

The titration schedule for Selank is designed to gradually increase the dose to evaluate individual response and tolerance. Initial dosing typically starts at 250 micrograms administered twice daily via the intranasal route during the first two weeks. Following this introductory phase, doses may be escalated to 500 micrograms, administered 2 to 3 times daily, from the third week onward. This gradual approach allows for careful monitoring of effects and minimizes the risk of adverse reactions, enabling researchers to tailor dosing to specific experimental needs.

The storage conditions for Selank vary based on its form. Lyophilized Selank should be stored at −20 °C (−4 °F) to maintain stability and prevent degradation. Once reconstituted, it is recommended to store the solution at a temperature range of 2 to 8 °C (35.6 to 46.4 °F). Under these conditions, the shelf life of the reconstituted peptide is approximately 28 days. Researchers should be mindful of these storage guidelines to ensure the peptide's efficacy and reliability in experimental applications.

Published studies indicate that Selank exhibits an excellent safety profile, with minimal adverse effects reported. Research suggests that Selank may provide benefits similar to low-dose benzodiazepines without the associated side effects, such as dependence and withdrawal symptoms. However, caution is advised in specific populations, including pregnant and breastfeeding individuals, due to insufficient safety data. Additionally, individuals with hypersensitivity to Selank or its components, as well as those concurrently using MAOI inhibitors, should be aware of potential contraindications and consider medical supervision.